COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,580 Articles (22,415 medRxiv, 8,165 bioRxiv)

Most recent first Previous |  Page 2259: Articles 22581-22590  | Next

The unintended consequences of inconsistent pandemic control policies
Althouse, B. M., Wallace, B., Case, B., Scarpino, S. V., Berdhal, A., White, E. R., Hebert-Dufresne, L.
10.1101/2020.08.21.20179473 — Posted: 2020-08-24
Correlation of National and Healthcare Workers COVID-19 Infection Data; Implications for Large-scale Viral Testing Programs
Wu, D., Mac Aonghusa, P., O'Shea, D.
10.1101/2020.08.21.20179283 — Posted: 2020-08-24
The effect of BMI and physical activity levels on the duration of symptomatic days with Covid-19 infection
Boukelia, B., S Alataibi, A. S.
10.1101/2020.08.21.20179499 — Posted: 2020-08-24
How do socio-demographic status and personal attributes influence adherence to COVID-19 preventive behaviours?
Uddin, S., Imam, T., Khushi, M., Khan, A., Moni, M. A.
10.1101/2020.08.21.20179663 — Posted: 2020-08-24
Comparing the COVID-19 pandemic in space and over time in Europe, using numbers of deaths, crude rates and adjusted mortality trend ratios
Gallo, V., Chiodini, P., Bruzzese, D., Kondilis, E., Howdon, D., Mierau, J., Bhopal, R.
10.1101/2020.08.21.20179218 — Posted: 2020-08-24
Quarantine and testing strategies in contact tracing for SARS-CoV-2
Quilty, B. J., Clifford, S., Flasche, S., Kucharski, A. J., CMMID COVID-19 Working Group, , Edmunds, W. J.
10.1101/2020.08.21.20177808 — Posted: 2020-08-24 Discussion: Onsite
Evidence for treatment with estradiol for women with SARS-CoV-2 infection
Seeland, U., Coluzzi, F., Simmaco, M., Mura, C., Bourne, P. E., Heiland, M., Preissner, R., Preissner, S.
10.1101/2020.08.21.20179671 — Posted: 2020-08-24 Discussion: Onsite
Randomized placebo-controlled trials of remdesivir in severe COVID-19 patients: A Systematic Review and Meta-analysis
Sarfraz, A., Sarfraz, Z., Sanchez-Gonalez, M. A., Michel, J., Michel, G., Frontela, O., Posada, J., Cardona, J., Angueira, E.
10.1101/2020.08.21.20179200 — Posted: 2020-08-24 Discussion: Onsite
Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands
Westerhuis, B. M., de Bruin, E., Chandler, F. D., Ramakers, C. R. B., Okba, N. M. A., Li, W., Goossens, H., de Jong, M. D., Bosch, B. J., Haagmans, B. L., Fraaij, P. L., Sikkema, R. S., Koopmans, M. P. G.
10.1101/2020.08.21.20177857 — Posted: 2020-08-24
Implications of the school-household network structure on SARS-CoV-2 transmission under different school reopening strategies in England
Munday, J. D., Sherratt, K., Meakin, S., Endo, A., Pearson, C. A. B., Hellewell, J., Abbott, S., Bosse, N., CMMID COVID-19 Working Group, , Atkins, K. E., Wallinga, J., Edmunds, W. J., van Hoek, A. J., Funk, S.
10.1101/2020.08.21.20167965 — Posted: 2020-08-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).